Sebastian Spencer
YOU?
Author Swipe
View article: A Systematic Review Investigates the Safety and Efficacy of Intravenous Iron Dosing in Peritoneal Dialysis
A Systematic Review Investigates the Safety and Efficacy of Intravenous Iron Dosing in Peritoneal Dialysis Open
Aims/Background Anaemia is a common complication in chronic kidney disease, particularly in people with advanced kidney failure, contributing to increased morbidity and mortality. Iron repletion and erythropoietin-stimulating agents are wi…
View article: Investigating the Impact of Ferric Derisomaltose (FDI) on Patient-Reported Quality-of-Life Outcome Measures in Iron-Deficient but Not Anaemic Patients with Chronic Kidney Disease
Investigating the Impact of Ferric Derisomaltose (FDI) on Patient-Reported Quality-of-Life Outcome Measures in Iron-Deficient but Not Anaemic Patients with Chronic Kidney Disease Open
Background/Objectives: Iron deficiency without anaemia (IDNA) is common in non-dialysis-dependent chronic kidney disease (CKD) and contributes to fatigue, reduced exercise tolerance, and impaired quality of life (QoL). While intravenous (I…
View article: On the Cusp—A Questionnaire‐Based Assessment of Implementing PIVOTAL Into UK Practice
On the Cusp—A Questionnaire‐Based Assessment of Implementing PIVOTAL Into UK Practice Open
Background Anemia is a common occurrence in people with chronic kidney disease and end‐stage kidney disease. Intravenous administration of iron is standard treatment for people undergoing maintenance hemodialysis. However, until the recent…
View article: Intravenous iron in chronic kidney disease without anaemia but iron deficiency: A scoping review
Intravenous iron in chronic kidney disease without anaemia but iron deficiency: A scoping review Open
Iron deficiency (ID) is a prevalent complication of chronic kidney disease (CKD), often managed reactively when associated with anaemia. This scoping review evaluates the evidence supporting intravenous (IV) iron therapy in non-anaemic ind…
View article: Cystatin C vs creatinine eGFR in advanced CKD: an analysis of the STOP-ACEi trial
Cystatin C vs creatinine eGFR in advanced CKD: an analysis of the STOP-ACEi trial Open
Background In this secondary analysis of the STOP-ACEi trial, we explored the impact of discontinuing or continuing renin–angiotensin system inhibitor therapy in people with advanced chronic kidney disease on cystatin C estimated glomerula…
View article: Cystatin C as a Marker of Kidney Function in Children
Cystatin C as a Marker of Kidney Function in Children Open
This review examines the reliability of cystatin C as a biomarker for kidney function in paediatric populations. Chronic kidney disease (CKD) affects a significant number of children globally, leading to severe health complications such as…
View article: WCN24-398 REPORT ON STOP-ACEi TRIAL: REVIEWING CYSTATIN C LEVELS IN CKD PATIENTS
WCN24-398 REPORT ON STOP-ACEi TRIAL: REVIEWING CYSTATIN C LEVELS IN CKD PATIENTS Open
In this pre-specified secondary analysis of the STOP-ACEi trial (1-2), we explored the impact of stopping or continuing renin angiotensin system (RAS) inhibitor therapy in people with advanced CKD on serum cystatin C levels.
View article: Unveiling the Untapped Potential: Cystatin C Testing in Kidney Function Assessment
Unveiling the Untapped Potential: Cystatin C Testing in Kidney Function Assessment Open
The burden of Chronic Kidney Disease (CKD) remains a growing public health problem. In 2019, the worldwide prevalence was estimated at 7.2 to 13.4%, with CKD incidence, prevalence, mortality and disability-adjusted life years having risen …
View article: Should Cystatin C eGFR Become Routine Clinical Practice?
Should Cystatin C eGFR Become Routine Clinical Practice? Open
Kidney function assessment is crucial for diagnosing and managing kidney diseases. Glomerular filtration rate (GFR) is widely used as an indicator of kidney function, but its direct measurement is challenging. Serum creatinine, a commonly …